Ablative Radiation Therapy

RADIATION2 trials

Sponsors

University of Michigan Rogel Cancer Center, Canadian Cancer Trials Group

Conditions

Prostate CancerProstate Cancer Metastatic

Phase 2

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

CompletedNCT03556904

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2018-12-10End: 2023-07-28Updated: 2026-01-15

Unknown Phase

Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

Active, not recruitingNCT03784755

Canadian Cancer Trials GroupProstate Cancer Metastatic

Start: 2019-11-15End: 2033-07-30Updated: 2026-03-27

Related Papers

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)

La radiologia medica2022-06-2810 citations

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

2020-09-1432 citations

Focal radiation for oligometastatic castration-resistant prostate cancer (FORCE): A phase II randomized trial.

Journal of Clinical Oncology2019-05-205 citations